Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

Giles, Jon T.; Ogdie, Alexis; Gómez-Reino, Juan J.; Helliwell, Philip S.; Germino, Rebecca; Stockert, Lori; Young, Pamela; Joseph, Wael; Mundayat, Rajiv; Graham, Daniela; Ritchlin, Christopher T.

doi:10.1136/rmdopen-2020-001486

Cited by 29 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tildrakizumab was as effective in overweight patients, who are often difficult to treat, as in non-overweight patients. 7 , 8 Although the sample number is limited to draw conclusions, we observed that tildrakizumab efficacy and safety were similar in patients who had previously received systemic biologic treatment for psoriasis and in patients naïve to biologic drugs.…”

Section: Discussionmentioning

confidence: 82%

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Burlando¹,

Castelli²,

Cozzani³

et al. 2021

DIC

View full text Add to dashboard Cite

Background Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patients eligible for systemic therapy. Methods We report our clinical experience with 26 patients followed up to 24 weeks. Results No adverse event was observed and no patient discontinued tildrakizumab. Whilst no patient had a Psoriasis Area and Severity Index (PASI) score of <5 at baseline, at week 4, 8 (32%) patients had a PASI score of <3 and 6 of these had a PASI score of 0. At week 12, 19 (79%) patients had a PASI score of <5 and, among these, 18 had a PASI score of <3 of whom 16 had a PASI score of 0. At week 24, 22 (96%) patients had a PASI score of <3 and 20 (87%) had a PASI score of 0. Quality of life was improved after 4 weeks and through the whole period of observation. Conclusion Our experience in the real-life setting confirms the efficacy and safety of tildrakizumab as demonstrated by clinical trials.

show abstract

Section: Discussionmentioning

confidence: 82%

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Burlando¹,

Castelli²,

Cozzani³

et al. 2021

DIC

View full text Add to dashboard Cite

show abstract

“…6 In patients with psoriatic arthritis, efficacy response rates to tofacitinib were generally reduced in patients with baseline BMI ≥35 kg/m 2 , compared with patients with lower baseline BMI. 7 …”

Section: Introductionmentioning

confidence: 99%

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme

Farraye

Qazi

Kotze

et al. 2021

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…В то же время недавно показано, что эффективность ингибитора янус-киназ (тофацитиниба) не зависит от ИМТ пациентов с ПсА [51].…”

Section: Discussionunclassified

The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register

Korsakova

Леонидовна²,

Коротаева

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To study the relationship between obesity, cardiometabolic disorders and disease activity in patients with psoriatic arthritis (PsA) in real practice. Materials and methods. The Russian register included 614 PsA patients [female 331 (54%)/283 (46%)]. Average age 45.20.52 years, PsA duration 5.70.27 years, psoriasis 15.710.56 years. Patients underwent examination, body mass index (BMI), PsA activity according to DAPSA, cDAPSA, analysis of concomitant diseases were assessed. The patients were divided into 3 groups depending on BMI (kg/m2): normal 25 (group 1), increased 2530 (group 2), obesity 30 (group 3). Results. The average BMI was 27.70.23 kg/m2, normal BMI in 213 (34.7%), increased in 214 (34.8%) and obesity in 187 (30.5%). Concomitant diseases in 297 (48%). In group 3, arterial hypertension was observed significantly more often than in groups 1 and 2 (p0.0001); more often than in group 2 diabetes mellitus (p0.0001), metabolic syndrome (p0.0001); more often than in group 1 ischemic heart disease (p=0.026). PsA activity at Baseline, after 6/12 months was significantly higher in group 3 (p0.031). In obese patients, the chance of a decrease in disease activity to a moderate/low level and remission during therapy for 6/12 months is 2.484 times lower than in group 1, and 2.346 times lower than in group 2: odds ratio 2.346 (95% сonfidence interval 1.075.143) and 2.484 (95% сonfidence interval 1.1355.439), respectively. Conclusion. In the majority (65.3%) of PsA patients, BMI exceeded the norm. Obesity is associated with a high incidence of cardiometabolic disorders, with higher PsA activity and lower treatment efficacy.

show abstract

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

Cited by 29 publications

References 39 publications

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme

The relationship between obesity, cardiometabolic disorders and disease activity in psoriatic arthritis patients: data from the Russian register

Contact Info

Product

Resources

About